U.S., March 19 -- ClinicalTrials.gov registry received information related to the study (NCT07478809) titled 'A Retrospective Real-World Study Based on RATIONALE-307' on March 05.
Brief Summary: The study aims to retrospectively collect long-term survival data from patients who received first-line tislelizumab combined with chemotherapy in the RATIONALE-307 trial, in order to enrich the evidence on long-term benefits in advanced squamous NSCLC patients from immunotherapy and to identify patients deriving greater clinical advantage.
Study Start Date: Feb. 28
Study Type: OBSERVATIONAL
Condition:
NSCLC (Advanced Non-small Cell Lung Cancer)
Intervention:
OTHER: No intervention
No intervention
Recruitment Status: ACTIVE_NOT_RECRUITING
...